Trade Amedisys - AMED CFD
Market information is presented
as of 2023-09-21
- Summary
Spread | 0.23 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026151% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003929% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Amedisys Inc ESG Risk Ratings
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Prev. Close* | 109.56 |
Open* | 109.3 |
1-Year Change* | -0.65% |
Day's Range* | 106.57 - 111.92 |
52 wk Range | 69.37-126.81 |
Average Volume (10 days) | 579.14K |
Average Volume (3 months) | 9.52M |
Market Cap | 3.03B |
P/E Ratio | 1,341.17 |
Shares Outstanding | 32.63M |
Revenue | 2.23B |
EPS | 0.07 |
Dividend (Yield %) | N/A |
Beta | 1.00 |
Next Earnings Date | Oct 24, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Jun 29, 2022 | 109.98 | 0.67 | 0.61% | 109.31 | 112.01 | 106.23 |
Jun 28, 2022 | 109.56 | -3.02 | -2.68% | 112.58 | 114.45 | 109.51 |
Jun 27, 2022 | 114.51 | -2.68 | -2.29% | 117.19 | 117.59 | 111.22 |
Jun 24, 2022 | 115.50 | 4.81 | 4.35% | 110.69 | 116.12 | 110.41 |
Jun 23, 2022 | 115.18 | 6.07 | 5.56% | 109.11 | 115.42 | 107.94 |
Jun 22, 2022 | 108.44 | 1.67 | 1.56% | 106.77 | 111.76 | 106.13 |
Jun 21, 2022 | 107.29 | -2.66 | -2.42% | 109.95 | 109.95 | 101.37 |
Jun 17, 2022 | 121.29 | 6.53 | 5.69% | 114.76 | 122.49 | 114.76 |
Jun 16, 2022 | 115.50 | 5.49 | 4.99% | 110.01 | 116.23 | 110.01 |
Jun 15, 2022 | 115.84 | 6.59 | 6.03% | 109.25 | 117.57 | 109.25 |
Jun 14, 2022 | 110.93 | 0.43 | 0.39% | 110.50 | 112.49 | 109.22 |
Jun 13, 2022 | 111.44 | -0.48 | -0.43% | 111.92 | 118.67 | 110.64 |
Jun 10, 2022 | 119.95 | 7.51 | 6.68% | 112.44 | 120.29 | 112.42 |
Jun 9, 2022 | 114.91 | 4.56 | 4.13% | 110.35 | 115.90 | 110.35 |
Jun 8, 2022 | 115.53 | 0.50 | 0.43% | 115.03 | 118.23 | 114.28 |
Jun 7, 2022 | 115.06 | 2.40 | 2.13% | 112.66 | 115.98 | 111.04 |
Jun 6, 2022 | 114.59 | -0.59 | -0.51% | 115.18 | 117.76 | 114.09 |
Jun 3, 2022 | 115.04 | 1.82 | 1.61% | 113.22 | 115.66 | 112.80 |
Jun 2, 2022 | 116.10 | 0.76 | 0.66% | 115.34 | 117.20 | 113.67 |
Jun 1, 2022 | 115.48 | -0.59 | -0.51% | 116.07 | 117.85 | 113.76 |
Amedisys Events
Time (UTC) | Country | Event |
---|---|---|
Tuesday, October 24, 2023 | ||
Time (UTC) 10:59 | Country US
| Event Q3 2023 Amedisys Inc Earnings Release Q3 2023 Amedisys Inc Earnings ReleaseForecast -Previous - |
Tuesday, February 13, 2024 | ||
Time (UTC) 10:59 | Country US
| Event Q4 2023 Amedisys Inc Earnings Release Q4 2023 Amedisys Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 2223.2 | 2214.11 | 2071.52 | 1955.63 | 1662.58 |
Revenue | 2223.2 | 2214.11 | 2071.52 | 1955.63 | 1662.58 |
Cost of Revenue, Total | 1251.43 | 1199.39 | 1185.37 | 1150.34 | 992.863 |
Gross Profit | 971.774 | 1014.72 | 886.15 | 805.296 | 669.715 |
Total Operating Expense | 2042.43 | 1962.2 | 1852.25 | 1778.16 | 1508.43 |
Selling/General/Admin. Expenses, Total | 754.058 | 711.24 | 668.3 | 607.926 | 501.306 |
Depreciation / Amortization | 24.935 | 30.901 | 28.802 | 18.428 | 13.261 |
Unusual Expense (Income) | 12.009 | 20.667 | -30.22 | 1.47 | 1 |
Operating Income | 180.772 | 251.915 | 219.268 | 177.472 | 154.148 |
Interest Income (Expense), Net Non-Operating | -22.095 | 26.571 | -6.78 | -9.099 | 0.6 |
Other, Net | 1.567 | 1.745 | -1.669 | 2.037 | 4.24 |
Net Income Before Taxes | 160.244 | 280.231 | 210.819 | 170.41 | 158.988 |
Net Income After Taxes | 117.699 | 210.166 | 185.184 | 127.907 | 120.129 |
Minority Interest | 0.91 | -1.094 | -1.576 | -1.074 | -0.783 |
Net Income Before Extra. Items | 118.609 | 209.072 | 183.608 | 126.833 | 119.346 |
Net Income | 118.609 | 209.072 | 183.608 | 126.833 | 119.346 |
Income Available to Common Excl. Extra. Items | 118.609 | 209.072 | 183.608 | 126.833 | 119.346 |
Income Available to Common Incl. Extra. Items | 118.609 | 209.072 | 183.608 | 126.833 | 119.346 |
Diluted Net Income | 118.609 | 209.072 | 183.608 | 126.833 | 119.346 |
Diluted Weighted Average Shares | 32.653 | 32.972 | 33.268 | 32.99 | 33.609 |
Diluted EPS Excluding Extraordinary Items | 3.63241 | 6.3409 | 5.51906 | 3.84459 | 3.55101 |
Diluted Normalized EPS | 3.96102 | 6.836 | 5.05118 | 4.26507 | 3.57349 |
Total Extraordinary Items |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 552.968 | 556.389 | 562.064 | 557.988 | 557.89 |
Revenue | 552.968 | 556.389 | 562.064 | 557.988 | 557.89 |
Cost of Revenue, Total | 297.455 | 315.01 | 316.167 | 318.227 | 313.211 |
Gross Profit | 255.513 | 241.379 | 245.897 | 239.761 | 244.679 |
Total Operating Expense | 621.173 | 514.01 | 515.826 | 519.057 | 510.249 |
Selling/General/Admin. Expenses, Total | 212.993 | 194.557 | 193.429 | 188.344 | 187.818 |
Depreciation / Amortization | 4.725 | 4.443 | 5.23 | 5.477 | 6.22 |
Unusual Expense (Income) | 106 | 1 | 7.009 | 3 | |
Operating Income | -68.205 | 42.379 | 46.238 | 38.931 | 47.641 |
Interest Income (Expense), Net Non-Operating | 1.231 | -6.988 | -5.314 | -4.602 | -7.616 |
Other, Net | 4.743 | -0.682 | 0.412 | 0.491 | 0.331 |
Net Income Before Taxes | -62.231 | 34.709 | 41.336 | 34.82 | 40.356 |
Net Income After Taxes | -80.481 | 24.909 | 31.546 | 25.403 | 29.037 |
Minority Interest | 0.206 | 0.337 | 0.171 | 0.239 | 0.542 |
Net Income Before Extra. Items | -80.275 | 25.246 | 31.717 | 25.642 | 29.579 |
Net Income | -80.275 | 25.246 | 31.717 | 25.642 | 29.579 |
Income Available to Common Excl. Extra. Items | -80.275 | 25.246 | 31.717 | 25.642 | 29.579 |
Income Available to Common Incl. Extra. Items | -80.275 | 25.246 | 31.717 | 25.642 | 29.579 |
Diluted Net Income | -80.275 | 25.246 | 31.717 | 25.642 | 29.579 |
Diluted Weighted Average Shares | 32.579 | 32.643 | 32.572 | 32.616 | 32.681 |
Diluted EPS Excluding Extraordinary Items | -2.46401 | 0.7734 | 0.97375 | 0.78618 | 0.90508 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.34915 | 0.7734 | 0.99718 | 0.94296 | 0.97113 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 388.961 | 356.684 | 361.984 | 350.554 | 224.118 |
Cash and Short Term Investments | 40.54 | 42.694 | 81.808 | 30.294 | 20.229 |
Cash & Equivalents | 40.54 | 42.694 | 81.808 | 30.294 | 20.229 |
Total Receivables, Net | 309.185 | 287.061 | 259.845 | 241.596 | 192.472 |
Accounts Receivable - Trade, Net | 300.385 | 278.861 | 259.645 | 239.596 | 190.872 |
Prepaid Expenses | 11.628 | 10.356 | 10.217 | 8.243 | 7.568 |
Other Current Assets, Total | 27.608 | 16.573 | 10.114 | 70.421 | 3.849 |
Total Assets | 1976.24 | 1856.97 | 1567.2 | 1262.74 | 717.118 |
Property/Plant/Equipment, Total - Net | 118.882 | 119.692 | 117.159 | 112.904 | 29.449 |
Property/Plant/Equipment, Total - Gross | 220.246 | 216.629 | 212.183 | 209.041 | 124.921 |
Accumulated Depreciation, Total | -101.364 | -96.937 | -95.024 | -96.137 | -95.472 |
Goodwill, Net | 1287.4 | 1196.09 | 932.685 | 658.5 | 329.48 |
Intangibles, Net | 101.167 | 111.19 | 74.183 | 64.748 | 44.132 |
Long Term Investments | 60.5 | 53.1 | 14.2 | 35.7 | 35.1 |
Other Long Term Assets, Total | 19.336 | 20.212 | 66.987 | 40.339 | 54.839 |
Total Current Liabilities | 355.529 | 374.282 | 456.337 | 326.943 | 222.476 |
Accounts Payable | 43.735 | 38.217 | 42.674 | 31.259 | 28.531 |
Accrued Expenses | 296.298 | 323.07 | 343.167 | 285.757 | 192.333 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 15.496 | 12.995 | 10.496 | 9.927 | 1.612 |
Total Liabilities | 924.672 | 925.617 | 757.974 | 622.295 | 235.536 |
Total Long Term Debt | 419.42 | 432.075 | 204.511 | 232.256 | 5.775 |
Long Term Debt | 418.32 | 431.375 | 203.611 | 230.556 | 5.775 |
Minority Interest | 55 | 44.972 | 1.517 | 1.063 | 1.051 |
Other Liabilities, Total | 74.312 | 74.288 | 95.609 | 62.033 | 6.234 |
Total Equity | 1051.57 | 931.351 | 809.224 | 640.45 | 481.582 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | ||
Common Stock | 0.038 | 0.038 | 0.038 | 0.037 | 0.036 |
Additional Paid-In Capital | 755.063 | 728.118 | 698.287 | 645.256 | 603.666 |
Retained Earnings (Accumulated Deficit) | 757.672 | 639.063 | 429.991 | 246.383 | 119.55 |
Treasury Stock - Common | -461.2 | -435.868 | -319.092 | -251.241 | -241.685 |
Other Equity, Total | 0 | 0.015 | 0.015 | ||
Total Liabilities & Shareholders’ Equity | 1976.24 | 1856.97 | 1567.2 | 1262.74 | 717.118 |
Total Common Shares Outstanding | 32.5183 | 32.51 | 32.8143 | 32.284 | 31.9735 |
Capital Lease Obligations | 1.1 | 0.7 | 0.9 | 1.7 | |
Other Current Liabilities, Total | 0 | 60 | |||
Deferred Income Tax | 20.411 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Total Current Assets | 405.557 | 388.961 | 388.78 | 394.869 | 392.485 |
Cash and Short Term Investments | 49.436 | 40.54 | 17.956 | 26.566 | 67.834 |
Cash & Equivalents | 49.436 | 40.54 | 17.956 | 26.566 | 67.834 |
Total Receivables, Net | 294.122 | 296.785 | 302.47 | 305.413 | 293.579 |
Accounts Receivable - Trade, Net | 294.122 | 296.785 | 302.47 | 305.413 | 293.579 |
Prepaid Expenses | 18.754 | 11.628 | 17.011 | 15.199 | 17.221 |
Other Current Assets, Total | 43.245 | 40.008 | 51.343 | 47.691 | 13.851 |
Total Assets | 1946.96 | 1976.24 | 1982.13 | 2000.99 | 1908.39 |
Property/Plant/Equipment, Total - Net | 118.564 | 118.882 | 123.091 | 125.57 | 120.096 |
Property/Plant/Equipment, Total - Gross | 138.536 | 117.39 | 119.655 | 118.112 | 115.868 |
Accumulated Depreciation, Total | -105.183 | -101.364 | -102.407 | -100.265 | -98.573 |
Goodwill, Net | 1244.68 | 1287.4 | 1285.45 | 1289.67 | 1204.64 |
Intangibles, Net | 99.929 | 101.167 | 103.678 | 106.189 | 106.534 |
Long Term Investments | 58.9 | 60.5 | 61.5 | 65 | 65 |
Other Long Term Assets, Total | 19.33 | 19.336 | 19.623 | 19.686 | 19.639 |
Total Current Liabilities | 353.05 | 355.529 | 367.2 | 427.372 | 380.154 |
Accounts Payable | 40.017 | 43.735 | 45.527 | 43.509 | 36.621 |
Accrued Expenses | 286.075 | 296.298 | 309.045 | 371.342 | 331.224 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 26.958 | 15.496 | 12.628 | 12.521 | 12.309 |
Other Current Liabilities, Total | |||||
Total Liabilities | 867.842 | 924.672 | 966.388 | 1015.34 | 941.634 |
Total Long Term Debt | 373.202 | 419.42 | 443.431 | 442.413 | 429.453 |
Long Term Debt | 373.202 | 419.42 | 443.431 | 442.413 | 429.453 |
Minority Interest | 54.231 | 55 | 53.871 | 53.349 | 53.894 |
Other Liabilities, Total | 64.607 | 74.312 | 85.903 | 86.027 | 75.218 |
Total Equity | 1079.12 | 1051.57 | 1015.74 | 985.646 | 966.758 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.038 | 0.038 | 0.038 | 0.038 | 0.038 |
Additional Paid-In Capital | 758.669 | 755.063 | 750.914 | 743.276 | 736.536 |
Retained Earnings (Accumulated Deficit) | 782.918 | 757.672 | 725.955 | 700.313 | 670.734 |
Treasury Stock - Common | -462.508 | -461.2 | -461.168 | -457.981 | -440.55 |
Total Liabilities & Shareholders’ Equity | 1946.96 | 1976.24 | 1982.13 | 2000.99 | 1908.39 |
Total Common Shares Outstanding | 32.5442 | 32.5183 | 32.4795 | 32.4325 | 32.5666 |
Deferred Income Tax | 22.752 | 20.411 | 15.983 | 6.179 | 2.915 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | 117.699 | 210.166 | 185.184 | 127.907 | 120.129 |
Cash From Operating Activities | 133.283 | 188.893 | 288.952 | 202 | 223.483 |
Cash From Operating Activities | 24.935 | 30.901 | 28.802 | 18.428 | 13.261 |
Deferred Taxes | 23.377 | 44.582 | -26.56 | 13.466 | 20.271 |
Non-Cash Items | 72.316 | 34.262 | 75.304 | 73.555 | 26.84 |
Cash Taxes Paid | 24.013 | 34.097 | 50.721 | 29.522 | 14.278 |
Cash Interest Paid | 27.694 | 5.291 | 6.207 | 9.628 | 3.522 |
Changes in Working Capital | -105.044 | -131.018 | 26.222 | -31.356 | 42.982 |
Cash From Investing Activities | -94.486 | -281.607 | -287.108 | -352.948 | -22.193 |
Capital Expenditures | -7.215 | -6.721 | -5.332 | -7.888 | -6.558 |
Other Investing Cash Flow Items, Total | -87.271 | -274.886 | -281.776 | -345.06 | -15.635 |
Cash From Financing Activities | -30.433 | 55.126 | -14.977 | 227.209 | -267.424 |
Financing Cash Flow Items | -5.938 | -81.187 | 4.385 | -11.465 | -10.093 |
Issuance (Retirement) of Stock, Net | -11.199 | -93.856 | 9.887 | 6.798 | -173.381 |
Issuance (Retirement) of Debt, Net | -13.296 | 230.169 | -29.249 | 231.876 | -83.95 |
Net Change in Cash | 8.364 | -37.588 | -13.133 | 76.261 | -66.134 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | 24.909 | 117.699 | 86.153 | 60.75 | 31.713 |
Cash From Operating Activities | 25.961 | 133.283 | 92.4 | 106.03 | 48.621 |
Cash From Operating Activities | 5.694 | 24.935 | 19.705 | 14.228 | 8.008 |
Deferred Taxes | 2.772 | 23.377 | 19.031 | 6.003 | 3.205 |
Non-Cash Items | 15.923 | 72.316 | 59.271 | 39.156 | 20.809 |
Cash Taxes Paid | 0.352 | 24.013 | 23.582 | 22.977 | 0.551 |
Cash Interest Paid | 6.654 | 27.694 | 9.153 | 4.489 | 1.864 |
Changes in Working Capital | -23.337 | -105.044 | -91.76 | -14.107 | -15.114 |
Cash From Investing Activities | 45.896 | -94.486 | -92.62 | -91.587 | -16.079 |
Capital Expenditures | -1.56 | -7.215 | -5.186 | -3.341 | -1.138 |
Other Investing Cash Flow Items, Total | 47.456 | -87.271 | -87.434 | -88.246 | -14.941 |
Cash From Financing Activities | -56.89 | -30.433 | -14.089 | -11.448 | -7.402 |
Financing Cash Flow Items | -2.393 | -5.938 | -9.047 | -4.785 | -4.702 |
Issuance (Retirement) of Stock, Net | 0.816 | -11.199 | -13.416 | -14.688 | 1.071 |
Issuance (Retirement) of Debt, Net | -55.313 | -13.296 | 8.374 | 8.025 | -3.771 |
Net Change in Cash | 14.967 | 8.364 | -14.309 | 2.995 | 25.14 |
Amedisys Company profile
About Amedisys Inc
Amedisys, Inc. is a healthcare services company, which is a multi-state provider of home health, hospice, and personal care services. The Company operates through three segments: Home Health, Hospice and Personal Care. The Home Health segment delivers a range of services in the homes of individuals who may be recovering from surgery, have a chronic disability or terminal illness or need assistance with important personal tasks. The Hospice segment provides palliative care and comfort to terminally ill patients and their families. The Personal Care segment provides patients with assistance with the essential activities of daily living. The Company owns and operates approximately 320 Medicare-certified home health care centers, 180 Medicare-certified hospice care centers and approximately 14 personal-care care centers in 39 states within the United States and the District of Columbia.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Amedisys Inc revenues increased 7% to $2.21B. Net income increased 14% to $209.1M. Revenues reflect Home Health Care segment increase of 8% to $1.35B, Hospice segment increase of 6% to $791.8M. Net income benefited from Home Health Care segment income increase of 21% to $271.7M, Other segment loss decrease of 5% to $185.5M.
Equity composition
Common Stock $.001 Par, 04/11, 60M auth., 30,084,676 issd., less 639,539 shs. in Treas. @ $14M. Insiders own 1.83%. 3/02, Exchangechanged from OTC Bulletin Board to NASDAQ. PO: 11/06, 3M shs. @ $41.5 per share by Raymond James. 12/06, 4-for-3 stock split.09/07, Name changed from Analytical Nursing Management.
Industry: | Home Healthcare Services |
3854 American Way Ste A
5959 S Sherwood Forest Blvd
BATON ROUGE
LOUISIANA 70816
US
News

EUR/USD tests key support
EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.
14:32, 21 September 2023
BoE leaves rates unchanged, GBP drops further as investors look for more clarity
The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August
11:45, 21 September 2023
GBP softer after CPI surprise, JPY focused on any further hints from Ueda
GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.
12:42, 20 September 2023
How to Trade The Break & Retest
In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.
11:59, 20 September 2023
Cable coils near lows ahead of Fed and BoE rate decisions
It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.
14:16, 19 September 2023
FTSE 100 Technical Outlook - 18 September 2023
In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.
06:55, 19 September 2023
Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally
The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.
13:46, 15 September 2023People also watch
Still looking for a broker you can trust?
Join the 555.000+ traders worldwide that chose to trade with Capital.com